The Hydration Pharmaceuticals Company Limited (ASX:HPC)
Australia · Delayed Price · Currency is AUD 0.0030
0.00 (0.00%)
Sep 1, 2026, 3:52 PM AEST
ASX:HPC Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.44 | 1.12 | 3.22 | 1.84 | 4.69 | 10.67 |
Cash & Short-Term Investments | 0.44 | 1.12 | 3.22 | 1.84 | 4.69 | 10.67 |
Cash Growth | -79.02% | -65.22% | 74.78% | -60.75% | -56.07% | 548.95% |
Accounts Receivable | 0.08 | 0.08 | 0.34 | 1.74 | 1.3 | 1.01 |
Other Receivables | - | 0 | 0.01 | 0 | 0.01 | 0 |
Receivables | 0.08 | 0.08 | 0.35 | 1.75 | 1.31 | 1.01 |
Inventory | 0.61 | 0.87 | 1.1 | 2.39 | 3.39 | 1.79 |
Prepaid Expenses | - | 0.12 | 0.33 | 0.71 | 1.01 | 1.83 |
Total Current Assets | 1.24 | 2.19 | 5 | 6.69 | 10.39 | 15.31 |
Total Assets | 1.24 | 2.19 | 5 | 6.69 | 10.39 | 15.31 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.54 | 0.15 | 0.28 | 1.06 | 0.45 | 0.57 |
Accrued Expenses | - | 0.42 | 1.39 | 2 | 1.87 | 1.49 |
Other Current Liabilities | 0.04 | 0.21 | 0.57 | 0.07 | 0.35 | - |
Total Current Liabilities | 0.58 | 0.77 | 2.23 | 3.13 | 2.68 | 2.06 |
Long-Term Debt | - | - | - | 3.89 | 3.71 | - |
Other Long-Term Liabilities | - | - | 0.02 | 0.02 | 0.02 | 0.02 |
Total Liabilities | 0.58 | 0.77 | 2.25 | 7.05 | 6.41 | 2.08 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 41 | 40.48 | 39.67 | 39.33 | 36.61 | 36.41 |
Retained Earnings | -44.33 | -43.27 | -40.41 | -43.08 | -34.98 | -24.37 |
Comprehensive Income & Other | 3.98 | 4.21 | 3.48 | 3.39 | 2.34 | 1.19 |
Shareholders' Equity | 0.66 | 1.42 | 2.74 | -0.36 | 3.98 | 13.23 |
Total Liabilities & Equity | 1.24 | 2.19 | 5 | 6.69 | 10.39 | 15.31 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | 3.89 | 3.71 | - |
Net Cash (Debt) | 0.44 | 1.12 | 3.22 | -2.05 | 0.98 | 10.67 |
Net Cash Growth | -79.02% | -65.22% | - | - | -90.85% | 548.95% |
Net Cash Per Share | 0.00 | 0.00 | 0.01 | -0.01 | 0.01 | 0.14 |
Filing Date Shares Outstanding | 440.47 | 430.8 | 304.91 | 265.14 | 163.76 | 161.03 |
Total Common Shares Outstanding | 440.47 | 430.8 | 304.91 | 265.14 | 163.76 | 161.03 |
Working Capital | 0.66 | 1.42 | 2.76 | 3.56 | 7.72 | 13.25 |
Book Value Per Share | 0.00 | 0.00 | 0.01 | -0.00 | 0.02 | 0.08 |
Tangible Book Value | 0.66 | 1.42 | 2.74 | -0.36 | 3.98 | 13.23 |
Tangible Book Value Per Share | 0.00 | 0.00 | 0.01 | -0.00 | 0.02 | 0.08 |